Cell Therapeutics Inc. is pursuing an unusual two-track approach of both appealing a "complete response" letter for its investigative non-Hodgkin’s lymphoma treatment Pixuvri (pixantrone dimaleate) and complying with the request in that letter to conduct another clinical trial. Pixuvri’s proposed indication is as a single-agent treatment for patients with relapsed or refractory, aggressive NHL who have received two or more prior lines of therapy. The Oncologic Drugs Advisory Committee will review...